Abstract
Prisc. (tolazoline, and adrenergic antagonits) is known to increase PaO2 in newborns with severe hypoxia due to a variety of causes. We used Prisc. in 33 infants with severe respiratory distress when PaO2 was <50 mmHg in F102 >0.8 and ventilatory peak pressure >35 cm. H2O. 11/33 developed ARF. Pertinent data of infants developing ARF (Gr. 1) and those without (Gr. 11) is shown in the table. There were no differences in birth weight & gestational age and initial pH and blood gas tension between the groups. Gr. I showed hypotension (42.4±1.5 to 38.0±1.6 mmHg),drop in urine output (2.4±0.8 to 0.14±.04 ml/kg/hr.) 24 hours following therapy. They also failed to show improvement in PaO2. Gr.11 had significantly higher BP (51.7±2.3 mmHg) than Gr. 1, (p<.01). A significant rise (p<.01) in P02 following Prisc. was also seen in this group. Urine output before and after Prisc. therapy was same (2.0±0.3 & 1.95±.34 ml/kg/hr). 9/11 (82%) in Gr. 1 & 8/22 (32%) in Gr. II died (p<.01). The data suggests that priscoline therapy in hypotensive neonates is associated with lack of rise in P02,ARF and increased mortality.Extreme caution is necessary before instituting Prisc. therapy.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bhat, R., Gupta, M., John, E. et al. 935 ACUTE RENAL-FAILURE (ARF) IN NEWBORN DUE TO PRISCO-LINE(PRISC). Pediatr Res 12 (Suppl 4), 519 (1978). https://doi.org/10.1203/00006450-197804001-00940
Issue Date:
DOI: https://doi.org/10.1203/00006450-197804001-00940